Ann: Mayne Pharma completes sale of Metrics Contract Services, page-3

Things worked out well for Richards still CEO when he and his board came up sale and decision to give away a substantial amount of sale proceeds to share holder's , Sott holding millions of ordinary shares ( cost him nothing) will do nicely with this arrangement . Now we're done with one of the few things we had generating an excellent return for us we now rely heavily on Nexstellis being successful , an unproven product which no one has a clue whether its going to be successful or not , guessing it'll be at least 2 years before we'll find out . Reason we couldn't get into net profit thanks to ongoing Teva write downs also added financial burden taking on and huge cost marketing Nexstellis . Syndicated lenders most likely withdrew their support . How else could board raise the kind of money needed to repay debt but sell our best asset .